Journal article
SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
J Lindsay, J Othman, Y Kong, A Yip, S Van Hal, S Larsen, C Bryant, J Gibson, I Kerridge, K Fay, W Stevenson, C Arthur, SCA Chen, DCM Kong, M Greenwood, SA Pergam, C Liu, MA Slavin
Open Forum Infectious Diseases | Published : 2021
DOI: 10.1093/ofid/ofab502
Open access
Abstract
Background. Itraconazole (ITZ) is an effective agent when used as primary invasive fungal disease (IFD) prophylaxis, but is limited by drug tolerability and variability in serum concentrations. A new formulation, SUBA-itraconazole (for “super bioavailability”; S-ITZ), addresses the limitations of conventional ITZ formulations. Methods. We conducted a retrospective cohort study at 2 Australian centers to evaluate the safety, tolerability, and effectiveness of S-ITZ as primary antifungal prophylaxis in hematopoietic cell transplant (HCT) recipients without grade II–IV acute graft-vs-host disease, from day 1 until approximately day 100 (cohort A) or day 1 until neutrophil engraftment (cohort B)..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
J. L. is supported by a Leukaemia Foundation/Haematology Society of Australia and New Zealand New Investigator PhD Scholarship. M. S. is supported by National Health and Medical Research Council Centres of Research Excellence Grant (1116876) and Investigator Grant (1173791).